Clinical Case Notes. Tachycardia and myocardial ischaemia following subconjunctival injection of mydricaine (number 02) for vitrectomy procedure
Authors:
- 1 February 2005
- journal article
- Published by Wiley in Clinical & Experimental Ophthalmology
- Vol. 33 (1) , 105-106
Abstract
Mydricaine is a mydriatic agent used routinely at the Royal Adelaide Hospital in subconjunctival injections that are given prior to all vitreoretinal surgery. The drug is manufactured by the hospital pharmacy and each vial of 0.4 mL mydricaine number 02 consists of a mixture of 1.3 mg atropine sulphate, 0.12 mg adrenaline and 8.4 mg procaine hydrochloride. Mydricaine is routinely used by many vitreoretinal units, even though the drug is not listed in the British National Formulary (BNF) or Monthly Index of Medical Specialities (MIMS). Therefore, published case reports provide the main forum for reporting side-effects. The case presented is of a patient with no previous ischaemic heart disease who developed transient myocardial ischaemia with tachycardia following the administration of subconjunctival mydricaine number 02. To the authors' knowledge this is the first case report documenting myocardial ischaemia in a patient with no previous ischaemic heart disease following mydricaine administration.Keywords
This publication has 5 references indexed in Scilit:
- Supraventricular ectopics and supraventricular tachycardia following injection of subconjunctival Mydricaine No. 2Eye, 2001
- The incidence of systemic side-effects following subconjunctival Mydricaine No. 1 injectionEye, 1999
- Haemodynamic responses to subconjunctival mydriatic agents (Mydricaine) used for maintenance of perioperative mydriasis in patients undergoing vitreoretinal surgeryEye, 1998
- Persistent tachycardia following subconjunctival injections of mydriatic agents (Mydricaine) used for maintenance of perioperative mydriasis in vitreoretinal surgeryEye, 1995
- Tachycardia and myocardial ischaemia following subconjunctival injection of Mydricaine No. 2Eye, 1994